191 related articles for article (PubMed ID: 34771087)
1. Identification of Novel Antagonists Targeting Cannabinoid Receptor 2 Using a Multi-Step Virtual Screening Strategy.
Wang M; Hou S; Liu Y; Li D; Lin J
Molecules; 2021 Nov; 26(21):. PubMed ID: 34771087
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel dual adenosine A1/A2A receptor antagonists using deep learning, pharmacophore modeling and molecular docking.
Wang M; Hou S; Wei Y; Li D; Lin J
PLoS Comput Biol; 2021 Mar; 17(3):e1008821. PubMed ID: 33739970
[TBL] [Abstract][Full Text] [Related]
3. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.
Pandey P; Roy KK; Doerksen RJ
J Biomol Struct Dyn; 2020 Jan; 38(1):32-47. PubMed ID: 30652534
[TBL] [Abstract][Full Text] [Related]
4. A pharmacoinformatic approach on Cannabinoid receptor 2 (CB2) and different small molecules: Homology modelling, molecular docking, MD simulations, drug designing and ADME analysis.
Vijayakumar S; Manogar P; Prabhu S; Pugazhenthi M; Praseetha PK
Comput Biol Chem; 2019 Feb; 78():95-107. PubMed ID: 30500557
[TBL] [Abstract][Full Text] [Related]
5. Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis.
Floresta G; Apirakkan O; Rescifina A; Abbate V
Molecules; 2018 Aug; 23(9):. PubMed ID: 30200181
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel CB2 Ligands through Virtual Screening and In Vitro Evaluation.
Stasiulewicz A; Lesniak A; Bujalska-Zadrożny M; Pawiński T; Sulkowska JI
J Chem Inf Model; 2023 Feb; 63(3):1012-1027. PubMed ID: 36693026
[TBL] [Abstract][Full Text] [Related]
7. Identification of new potent A
Wei Y; Wang M; Li Y; Hong Z; Li D; Lin J
Eur J Med Chem; 2020 Feb; 187():111936. PubMed ID: 31855793
[TBL] [Abstract][Full Text] [Related]
8. Difference and Influence of Inactive and Active States of Cannabinoid Receptor Subtype CB2: From Conformation to Drug Discovery.
Hu J; Feng Z; Ma S; Zhang Y; Tong Q; Alqarni MH; Gou X; Xie XQ
J Chem Inf Model; 2016 Jun; 56(6):1152-63. PubMed ID: 27186994
[TBL] [Abstract][Full Text] [Related]
9. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor.
Salo OM; Raitio KH; Savinainen JR; Nevalainen T; Lahtela-Kakkonen M; Laitinen JT; Järvinen T; Poso A
J Med Chem; 2005 Nov; 48(23):7166-71. PubMed ID: 16279774
[TBL] [Abstract][Full Text] [Related]
10. In Silico Prediction and Validation of CB2 Allosteric Binding Sites to Aid the Design of Allosteric Modulators.
Yuan J; Jiang C; Wang J; Chen CJ; Hao Y; Zhao G; Feng Z; Xie XQ
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056767
[TBL] [Abstract][Full Text] [Related]
11. Deciphering the Interactions of Bioactive Compounds in Selected Traditional Medicinal Plants against Alzheimer's Diseases via Pharmacophore Modeling, Auto-QSAR, and Molecular Docking Approaches.
Ojo OA; Ojo AB; Okolie C; Nwakama MC; Iyobhebhe M; Evbuomwan IO; Nwonuma CO; Maimako RF; Adegboyega AE; Taiwo OA; Alsharif KF; Batiha GE
Molecules; 2021 Apr; 26(7):. PubMed ID: 33915968
[TBL] [Abstract][Full Text] [Related]
12. Examining the critical roles of human CB2 receptor residues Valine 3.32 (113) and Leucine 5.41 (192) in ligand recognition and downstream signaling activities.
Alqarni M; Myint KZ; Tong Q; Yang P; Bartlow P; Wang L; Feng R; Xie XQ
Biochem Biophys Res Commun; 2014 Sep; 452(3):334-9. PubMed ID: 25148941
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone-Based Cannabinoid Receptor Type 2 Ligands.
Ragusa G; Bencivenni S; Morales P; Callaway T; Hurst DP; Asproni B; Merighi S; Loriga G; Pinna GA; Reggio PH; Gessi S; Murineddu G
ChemMedChem; 2018 Jun; 13(11):1102-1114. PubMed ID: 29575721
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists.
Pandey P; Roy KK; Liu H; Ma G; Pettaway S; Alsharif WF; Gadepalli RS; Rimoldi JM; McCurdy CR; Cutler SJ; Doerksen RJ
Molecules; 2018 Oct; 23(10):. PubMed ID: 30322136
[TBL] [Abstract][Full Text] [Related]
15. 7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands.
Penthala NR; Shoeib A; Dachavaram SS; Cabanlong CV; Yang J; Zhan CG; Prather PL; Crooks PA
Bioorg Med Chem Lett; 2020 Nov; 30(22):127501. PubMed ID: 32882418
[TBL] [Abstract][Full Text] [Related]
16. The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies.
Chen JJ; Han S; Cao Y; Chen JZ
Yao Xue Xue Bao; 2013 Sep; 48(9):1436-49. PubMed ID: 24358778
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel agonists and antagonists of the ecdysone receptor by virtual screening.
Hu X; Yin B; Cappelle K; Swevers L; Smagghe G; Yang X; Zhang L
J Mol Graph Model; 2018 May; 81():77-85. PubMed ID: 29529496
[TBL] [Abstract][Full Text] [Related]
18. GPCR structure-based virtual screening approach for CB2 antagonist search.
Chen JZ; Wang J; Xie XQ
J Chem Inf Model; 2007; 47(4):1626-37. PubMed ID: 17580929
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
20. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
Jana S; Singh SK
J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
